OVERVIEW Balancing the costs and benefits of GLP-1s Glucagon-like peptide-1 (GLP-1) medications have been hailed as medical breakthroughs
Benichou O, Coskun T, Gonciarz MD, Garhyan P, Adams AC, Du Y, et al
Ongoing research highlights the significant clinical potential of incretin-based therapies, especially in emerging areas such as central nervous system disorders, substance use, and post-transplant care
Department of Health and Human Services recommends 150300 minutes of moderate-intensity aerobic activity weekly, plus muscle-strengthening activities on 2 or more days per week
The Health Sciences Authority (HSA) is looking into the matter
If you are comparing your options across the full GLP-1 landscape, the semaglutide vs tirzepatide comparison provides context for both injectable and oral formats